Editas是由CRISPR-Cas9的发明者之一，MIT华裔年轻教授张锋参与发起成立的。Editas公司主攻基因编辑及致命性遗传病治疗技术，现阶段主要负责开发利用Crispr-Cas9治疗技术。它尝试利用Crispr基因组编辑技术，修复能导致眼疾的问题基因，并在与开发癌症治疗新技术的Juno Therapeutics进行合作，但Editas的治疗技术尚未进入人体试验阶段。这种方法能够通过DNA剪切技术治疗多种疾病。这一成果受到了众多投资公司和生物医药巨头的关注。

Editas的治疗技术尚未进入人体试验阶段，也没有披露人体试验的时间表，但单是身在生物医药产业，而且处在最前沿的基因治疗领域，已经足以让Editas获得众投资公司和生物制药机构的“抢食”了。

Editas Medicine is a transformative genome editing company founded by world leaders in the fields of genome editing, protein engineering, and molecular and structural biology, with specific expertise in CRISPR/Cas9 and TALENs technologies.
The company's mission is to translate its genome editing technology into a novel class of human therapeutics that enable precise and corrective molecular modification to treat the underlying cause of a broad range of diseases at the genetic level. The company has generated substantial patent filings and has access to intellectual property covering foundational genome editing technologies, as well as essential advancements and enablements that will uniquely allow the company to translate early findings into viable human therapeutic products.

Editas was founded in 2013 with $43 million in Series A venture capital financing led by leading health care venture capital firms Flagship Ventures, Polaris Partners and Third Rock Ventures with participation from Partners Innovation Fund.